tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Sean Laaman, 24 are a HOLD (34.78%), 42 are a BUY (60.87%), 3 are a SELL (4.35%).
Analyst Sean Laaman, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 45.86% that have a potential upside of 21.42% achieved within 60 days.
Sean Laaman’s has documented 131 price targets and ratings displayed on 16 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on ARGX, argenx NV ADR at 17-Aug-2026.
Analyst best performing recommendations are on RXRX (RECURSION PHARMACEUTICALS).
The best stock recommendation documented was for RMD (RESMED) at 4/25/2024. The price target of $207 was fulfilled within 1 day with a profit of $26.84 (14.9%) receiving and performance score of 148.98.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 13-Oct-2025
$215
$-9.46 (-4.21%)
$225
Buy Since 06-Feb-2024
$255
$30.54 (13.61%)
$290
Hold Since 07-Aug-2026
$244
$19.54 (8.71%)
$234
Hold Since 10-Jan-2025
$225
$0.54 (0.24%)
$275
Buy Since 14-Apr-2023
$220
$-4.46 (-1.99%)
$300
Which stock is Sean Laaman is most bullish on?
Which stock is Sean Laaman is most reserved on?
What Year was the first public recommendation made by Sean Laaman?
